Investors often look at CNC and UNH together because both play in managed care, yet they follow distinct strategies. Centene Corporation concentrates on Medicaid, Medicare, and Affordable Care Act Marketplace plans, which ties it closely to government policy and reimbursement rates. UnitedHealth Group pairs its UnitedHealthcare insurance operations with the broader Optum platform spanning pharmacy, care delivery, and data analytics. This comparison matters most when evaluating relative performance, turnaround progress, and how each name balances risk and reward in the current environment. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Centene stands as one of the largest managed care organizations in the United States, primarily serving under-insured and government-sponsored populations. After facing challenges in 2025 that led to a withdrawal of earnings guidance amid elevated medical costs, CNC has shown a clear recovery. Its health benefits ratio has improved steadily, and management has raised its 2026 outlook multiple times, most recently lifting the full-year adjusted earnings floor above $5.20 per share after a solid third quarter. Medicare Advantage reached breakeven ahead of schedule, and Marketplace margins have widened. Medicaid membership attrition continues as a headwind, yet pricing actions and cost discipline have helped support sentiment. The stock has ranked among the stronger performers in the sector over the past year and has traded near its 52-week high in recent weeks.
UnitedHealth Group operates as the largest U.S. health insurer and a diversified healthcare services company through UnitedHealthcare and the Optum platform. Following a difficult 2025 period with rising medical costs and federal scrutiny, UNH has advanced its turnaround under CEO Stephen Hemsley. In the latest quarter, adjusted earnings per share rose sharply year over year, prompting the company to raise its full-year adjusted earnings guidance to at least $20.50 per share, helped by a lower medical care ratio. The insurer has intentionally reduced exposure to less profitable members and markets, which has tempered revenue growth but lifted margins. Optum Health’s operating earnings have rebounded, and the company has highlighted AI-driven efficiency efforts. The stock maintains a low beta and has moved forward at a more measured pace than Centene in recent activity.
The most obvious difference lies in scope. UNH benefits from diversification through its Optum segment, which supplies earnings stability beyond core insurance, while CNC remains more focused on government-funded programs, heightening both its potential upside and its exposure to policy shifts. On growth drivers, UnitedHealth emphasizes margin recovery, cost control, and AI efficiency while shrinking toward profitability, whereas Centene rebuilds earnings via repricing, favorable rate actions, and reduced exposure to underpriced plans. Recent momentum has clearly favored Centene, which has outperformed on both a year-to-date and trailing one-year basis. UnitedHealth, however, provides greater stability, a lower beta, a larger market capitalization, and a more diversified revenue base. Centene continues to navigate Medicaid membership declines and regulatory exposure, while UnitedHealth addresses commercial medical-cost trends and legal scrutiny over Medicare Advantage billing. From a valuation perspective, Centene trades at a lower forward earnings multiple, reflecting its higher perceived execution risk compared with UnitedHealth’s scale and diversification.
Based on factors such as trend consistency, earnings-estimate revisions, and relative market positioning, Tickeron’s AI currently favors CNC over UNH. Centene’s stronger price momentum, improving health benefits ratio, and repeated upward guidance revisions point to a more forceful positive trend and favorable estimate-revision dynamics. UnitedHealth’s lower volatility and diversified model position it as a steadier, more defensive option, yet its more moderate momentum and revenue contraction result in a less compelling relative trend signal at present. This assessment remains probabilistic rather than absolute, reflecting the balance of momentum and revision strength in Centene’s favor while recognizing the distinct catalysts and risks each name carries.
When evaluating names like these, I often turn to Tickeron’s AI Trend Prediction Engine to cross-check momentum signals and estimate-revision trends against broader sector data. It provides a structured way to quantify the factors already visible in price action and fundamentals, helping confirm whether the observed edge in one name holds up under additional quantitative scrutiny. This step fits naturally into a broader review that also includes earnings transcripts and valuation metrics.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
It is expected that a price bounce should occur soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +1.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where UNH advanced for three days, in 187 of 331 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
UNH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on UNH as a result. In 56 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 67%.
The Moving Average Convergence Divergence Histogram (MACD) for UNH turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 27 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 59%.
UNH moved below its 50-day moving average on November 17, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for UNH crossed bearishly below the 50-day moving average on November 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 67%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UNH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 52%.
The Aroon Indicator for UNH entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 58 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. UNH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.594) is normal, around the industry mean (3.520). P/E Ratio (25.266) is within average values for comparable stocks, (126.353). Projected Growth (PEG Ratio) (1.025) is also within normal values, averaging (0.786). UNH has a moderately high Dividend Yield (0.024) as compared to the industry average of (0.009). P/S Ratio (0.757) is also within normal values, averaging (0.569).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UNH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of hospital and medical service plans
Industry ManagedHealthCare